Case Study: a Fortune 100 company launches two products 11 months faster with RegDesk

Gap Analysis of Centrally Authorized Drugs in EU

A subsidiary of a Fortune 100 company needed to introduce two new pharmaceutical products across 18 European and non-European countries. Their challenge was to identify country-specific regulations and avoid the risk of inaccurate information, a problem they had encountered with a previous consulting agency. To solve this, they chose RegDesk and its regulatory intelligence product.

RegDesk implemented a solution by crowdsourcing expertise from 54 vetted consultants across the target countries to provide a comprehensive, peer-reviewed gap analysis. This allowed the company to cut its regulatory strategy timeline by 88%, reduce regulatory risk by 75%, and save 11 months of time, accelerating their product launch significantly.